Sarepta Therapeutics, Inc. (SRPT)

23.21 -0.13 (-0.56%)

As of 2025-10-16 22:19:27 EST

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

Traded asNasdaq: SRPT
ISINUS8036071004
CIK0000873303
LEI549300IKDPIED8J8IG21
EIN930797222
Sector—
IndustryPharmaceutical Preparations
CEODouglas S. Ingram
Employees1,314
Fiscal Year End1231
Address215 FIRST STREET, CAMBRIDGE, MA, 02142
Phone617-274-4000
Websitehttp://sarepta.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
SRPTSarepta Therapeutics, Inc.2025-10-16 22:19:2723.21-0.13-0.56
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
SRPT0000873303Sarepta Therapeutics, Inc.US8036071004549300IKDPIED8J8IG21930797222Nasdaq2834Pharmaceutical Preparations1231DE215 FIRST STREETCAMBRIDGEMA02142UNITED STATESUS617-274-4000215 FIRST STREET, CAMBRIDGE, MA, 02142215 FIRST STREET, CAMBRIDGE, MA, 02142Sarepta Therapeutics, Inc.—1980Douglas S. Ingram1,314http://sarepta.com15,054,650,800,00098,356,95097,713,438Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.2025-10-10 20:47:25
This is a preview of the latest data. Subscribe to access the full data.
SRPT Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
SRPT Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202415,054,650,800,0004,372,964,885,00040.938997,032,0733,176,6633.3846
202310,681,685,915,0004,120,039,902,00062.789793,855,4105,873,5256.6758
20226,561,646,013,0006,555,439,996,849105,630.40587,981,885832,2960.955
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Louise Rodino-KlapacChief Scientific Officer, Executive Vice President2024666,706—772,020436,58816,7202,737,283
Bilal ArifExecutive Vice President2024545,200—772,020358,28018,3882,539,138
Douglas S. IngramChief Executive Officer, President2024846,902—01,111,14820,0361,978,086
Ian M. EstepanChief Financial Officer, Executive Vice President2024656,961—772,020430,20648,0852,752,522
Dallan MurrayExecutive Vice President2024621,842—772,020409,43517,7762,666,323
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20241,372
20231,314
20221,162
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue1,901,979,0001,243,336,000933,013,000
Cost Of Revenue-22,247,000——
Gross Profit———
Research And Development Expenses804,522,000877,387,000877,090,000
General And Administrative Expenses557,872,000481,871,000451,421,000
Operating Expenses1,683,898,0001,511,160,0001,469,214,000
Operating Income218,081,000-267,824,000-536,201,000
Net Income235,239,000-535,977,000-703,488,000
Earnings Per Share Basic2.47-5.8-8.03
Earnings Per Share Diluted2.34-5.8-8.03
Weighted Average Shares Outstanding Basic95,075,00092,398,00087,559,000
Weighted Average Shares Outstanding Diluted107,875,00092,398,00087,559,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents1,487,955,0001,676,250,0001,989,374,000
Marketable Securities Current251,782,0001,247,820,0001,022,597,000
Accounts Receivable601,988,000400,327,000214,628,000
Inventories749,960,000322,859,000203,968,000
Non Trade Receivables———
Other Assets Current90,461,000179,895,000149,891,000
Total Assets Current3,073,463,0002,579,331,0002,557,861,000
Marketable Securities Non Current133,163,000428,430,000—
Property Plant And Equipment340,336,000227,154,000180,037,000
Other Assets Non Current79,915,000136,771,000317,936,000
Total Assets Non Current889,710,000685,245,000570,505,000
Total Assets3,963,173,0003,264,576,0003,128,366,000
Accounts Payable214,442,000164,918,00095,875,000
Deferred Revenue130,256,00050,416,00089,244,000
Short Term Debt0105,483,0000
Other Liabilities Current13,473,000314,997,00015,489,000
Total Liabilities Current731,684,000653,659,000619,604,000
Long Term Debt1,137,124,0001,237,998,0001,544,292,000
Other Liabilities Non Current1,750,0003,000,00042,000
Total Liabilities Non Current1,703,747,0001,751,580,0002,123,812,000
Total Liabilities2,435,431,0002,405,239,0002,743,416,000
Common Stock10,0009,0009,000
Retained Earnings-4,210,974,000-4,446,213,000-3,910,236,000
Accumulated Other Comprehensive Income-218,000918,000-1,664,000
Total Shareholders Equity1,527,742,000859,337,000384,950,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization37,724,00044,397,00041,864,000
Share Based Compensation Expense184,300,000182,514,000233,018,000
Other Non Cash Income Expense-2,130,000-37,0009,643,000
Change In Accounts Receivable201,661,000185,699,00061,638,000
Change In Inventories395,170,000147,714,00050,780,000
Change In Non Trade Receivables———
Change In Other Assets9,676,00010,713,000-14,620,000
Change In Accounts Payable———
Change In Other Liabilities———
Cash From Operating Activities-205,787,000-500,993,000-325,346,000
Purchases Of Marketable Securities1,099,595,0002,044,940,0001,936,856,000
Sales Of Marketable Securities2,002,112,0001,868,482,000923,224,000
Acquisition Of Property Plant And Equipment136,956,00076,106,00030,824,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities755,561,000-165,803,000-1,046,883,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock——0
Repurchase Of Common Stock0——
Issuance Of Long Term Debt——0
Repayment Of Long Term Debt00550,000,000
Other Financing Activities———
Cash From Financing Activities124,806,000125,004,000232,507,000
Change In Cash674,580,000-541,792,000-1,139,722,000
Cash At End Of Period1,487,955,0001,676,250,0001,989,374,000
Income Taxes Paid22,587,00015,081,0001,695,000
Interest Paid15,856,00015,923,00044,418,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share2.47-5.8-8.03
Price To Earnings Ratio49.2267-16.6259-16.137
Earnings Growth Rate-142.5862-27.770955.9223
Price Earnings To Growth Ratio-0.34520.5987-0.2886
Book Value Per Share16.06889.30044.3965
Price To Book Ratio7.566810.368429.4737
Ebitda277,159,000-454,489,000-606,681,000
Enterprise Value11,209,338,2508,577,170,14010,900,813,220
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.74431.56344.0117
Capital Expenditures150,906,00091,514,00030,745,000
Free Cash Flow-356,693,000-592,507,000-356,091,000
Return On Equity0.154-0.6237-1.8275
One Year Beta0.350.90050.9381
Three Year Beta0.82110.84370.8744
Five Year Beta0.83910.93081.0094
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Rothfuss CristinEVP, General Counsel2025-09-0393,875A114,985
Rothfuss CristinEVP, General Counsel2025-09-0325,000A139,985
Estepan Ian MichaelChief Operating Officer2025-09-0393,875A156,487
Estepan Ian MichaelChief Operating Officer2025-09-0350,000A206,487
Wong Ryan Ho-YanChief Financial Officer2025-09-0393,875A111,203
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Gilbert Cisneros2025-05-06CA31Sale2025-04-14—$1,001 - $15,000
Josh Gottheimer2023-08-21NJ05Purchase2023-07-14Joint$1,001 - $15,000
Josh Gottheimer2023-07-11NJ05Sale2023-06-13Joint$1,001 - $15,000
Daniel Goldman2023-05-19NY10Sale2023-04-10—$15,001 - $50,000
Josh Gottheimer2023-04-20NJ05Purchase2023-03-06Joint$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Blue Trust, Inc.2025-09-303471819.2778
CWM, LLC2025-09-301,401,00072,70519.2697
Inspire Investing, LLC2025-09-30351,50418,24119.27
ATWOOD & PALMER INC2025-09-3026,9781,40019.27
YOUSIF CAPITAL MANAGEMENT, LLC2025-09-30486,04725,22319.27
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Pacer Funds Trust2025-07-31Pacer Trendpilot US Mid Cap ETFPTMC13,944228,960.480.0546
ETFis Series Trust I2025-07-31Virtus LifeSci Biotech Products ETFBBP11,911195,578.620.7936
Direxion Shares ETF Trust2025-07-31Direxion Daily Mid Cap Bull 3X SharesMIDU1,71128,094.620.0377
INVESCO EXCHANGE-TRADED FUND TRUST2025-07-31Invesco RAFI US 1500 Small-Mid ETFPRFZ3,05250,113.840.0021
INVESCO EXCHANGE-TRADED FUND TRUST2025-07-31Invesco S&P MidCap 400 Pure Growth ETFRFG40,363662,760.460.222
This is a preview of the latest data. Subscribe to access the full data.